Back Hepatitis B Hepatitis B Topics HBV Disease Progression Hepatitis Delta (HDV)

EASL 2015: Prenylation Inhibitor Lonafarnib Lowers Hepatitis Delta Viral Load During Therapy

Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log in a Phase 2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Combining lonafarnib with pegylated interferon for 8 weeks led to significantly greater HDV RNA declines than lonafarnib alone, but boosting with ritonavir achieved an even greater effect with an all-oral regimen. HDV viral load rose again after stopping therapy, however, and researchers are now evaluating longer treatment durations.

alt

Read more:

EASL 2015: Nucleic Acid Polymer REP 2139-Ca Shows Promise Against Hepatitis B and Delta Viruses

The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more:

Hepatitis Delta Found in 15% of HIV/HBV Coinfected People, Increases Risk of Death

Approximately 15% of people with HIV who test positive for hepatitis B surface antigen (HBsAg) also carry hepatitis delta virus (HDV), a defective virus that can only replicate in the presence of hepatitis B virus (HBV) but can lead to more severe liver damage, according to a recent European study.alt

Read more:

EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse

Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49thEASL International Liver Congress last week in London.

 

alt

Read more:

One-quarter of Patients Clear Hepatitis Delta with Pegylated Interferon

Treatment with pegylated interferon (Pegasys) -- either alone or in combination with the antiviral drug adefovir (Hepsera) -- led to clearance of hepatitis delta virus (HDV) and improvement in liver enzyme levels, according to a small study published in the January 27, 2011, New England Journal of Medicine. Adefovir alone, however, had no effect on HDV.

Read more: